Journal of Cardiovascular Pharmacology最新文献

{"title":"Androgen Replacement Therapy for Torsades de Pointes in Males: Hormonal Modulation as a Novel Antiarrhythmic Strategy.","authors":"Riccardo Accioli, Pier Leopoldo Capecchi, Mohamed Boutjdir, Pietro Enea Lazzerini","doi":"10.1097/FJC.0000000000001749","DOIUrl":"10.1097/FJC.0000000000001749","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"340-342"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144775454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rare but Severe Cardiovascular Complications of SARS-CoV-2 Vaccination: A Call for Awareness.","authors":"Michele Marchetta, Michele Golino, John D Markley, Antonio Abbate","doi":"10.1097/FJC.0000000000001740","DOIUrl":"10.1097/FJC.0000000000001740","url":null,"abstract":"<p><strong>Abstract: </strong>The extensive use of severe acute respiratory syndrome coronavirus 2 vaccines has played a crucial role in controlling the coronavirus disease 2019 pandemic, underscoring the remarkable advantages and efficacy of novel vaccine technologies. However, rare but life-threatening cardiovascular complications such as myocarditis, pericarditis, and thrombosis have emerged, predominantly affecting young males after their second vaccine dose. These adverse events highlight the importance of continued pharmacovigilance and transparent communication about potential risks. Because the global epidemiologic context has shifted, now characterized by widespread natural, vaccine-induced, or hybrid immunity, it is important to re-evaluate the risk-benefit ratio of repeated vaccine administration in low-risk individuals. Data regarding severe acute respiratory syndrome coronavirus 2 vaccines complications are still largely based on the early phases of the pandemic (2020-2021), when population-level immunity was minimal and severe coronavirus disease 2019 outcomes more frequent. Today, such comparisons may no longer be appropriate. Updated real-world evidence is needed to better inform decision making and ensure that public health strategies remain aligned with the contemporary risk landscape.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"317-320"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Apigenin on the Apoptosis Index of Atherosclerosis.","authors":"Zhuo-Nan Jia, Bo-Yu Zhang, Zhi-Yuan Gao, Jia-Xing Wang, Han-Bing Liu, Xin-Yang He, Jian-Zhao Wu, Li-Ying Luo, Ze-Hui Zhang, Yi-Xuan Huang, Qian Xu","doi":"10.1097/FJC.0000000000001736","DOIUrl":"10.1097/FJC.0000000000001736","url":null,"abstract":"<p><strong>Abstract: </strong>Recently, apigenin has been widely studied for its antiatherosclerosis properties, but its mechanism remains to be further elucidated. This study aims to evaluate the expression of LOX-1, Bcl-2, and Bax in apigenin-treated atherosclerotic rats and to explore whether apigenin affect the expression of apoptotic genes. We analyzed the relationship between these 3 genes and atherosclerosis based on bioinformatics methods and conducted animal experiments on them. We used a fully automatic analyzer to analyze blood lipid levels and found that apigenin had a good effect on lowering blood lipids. Western blot was used to detect LOX-1 protein, and RT-qPCR was used to detect Bcl-2 and Bax mRNA.The fruit showed that apigenin treatment reduced LOX-1 gene expression while increasing the Bcl-2/Bax ratio. These studies provide an experimental basis for the development of apigenin as a new drug for the treatment of atherosclerosis.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"350-373"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relevance of CYP2D6 in the Efficacy and Toxicity of Flecainide in Patients With Atrial Fibrillation: A Cohort Study.","authors":"Mauro Trincado Ave, María Brión, Alejandro Blanco-Verea, Almudena Gil, Carlos Tilves, Ana Seoane Blanco, María Moure González, Federico García-Rodeja, Pablo de la Fuente, José Ramón González-Juanatey, Moisés Rodríguez Mañero","doi":"10.1097/FJC.0000000000001739","DOIUrl":"10.1097/FJC.0000000000001739","url":null,"abstract":"<p><p>A 25% flecainide dose reduction has been recommended for intermediate metabolizers (IMs); however, studies have yielded contradictory results, likely because of the lack of standardization in CYP2D6 pharmacogenetic classifications. We aimed to address this gap. This cohort study included atrial fibrillation patients prescribed flecainide between 2017 and 2021. CYP2D6 was analyzed, and patient phenotypes were classified using the current standard. For the primary outcome-6-month toxicity or recurrence-normal metabolizers (NMs) were compared with IMs. As a secondary objective, outcomes in poor metabolizers (PMs) and 12-month results were evaluated. A total of 104 patients were enrolled. Overall, 50% were NMs, 36.5% IMs, 6.7% PMs, and 6.7% others. There were no differences between IMs and NMs in the incidence of the primary outcome (29.0% vs. 28.9%, P = 0.99). No significant differences were observed in multivariate analysis ( P = 0.97) or 12-month follow-up ( P = 0.57). PMs had a lower event rate at 6 months ( P = 0.1), which became significant when the follow-up was extended to 1 year (univariate P = 0.04; multivariate P = 0.03). Using a standardized CYP2D6 classification, IMs and NMs showed similar rates of toxicity and recurrence when treated with 100 mg flecainide every 12 hours. Although the small sample size limits definitive conclusions, our findings challenge current recommendations to adjust dosing between NMs and IMs. By contrast, better outcomes were observed in PMs. This raises the question of whether, in an effort to minimize flecainide toxicity, dosing has inadvertently been standardized to subtherapeutic levels for all groups except PMs.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"384-390"},"PeriodicalIF":2.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time to combinatorial regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology Patients.","authors":"Vincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, Martina Iovine, Raffaele Arianna, Matteo Barbato, Maria Laura Canale, Andrea Paccone, Alessandro Inno, Marino Scherillo, Stefano Oliva, Christian Cadeddu Dessalvi, Carlo Maurea, Alfredo Mauriello, Celeste Fonderico, Anna Chiara Maratea, Domenico Gabrielli, Nicola Maurea","doi":"10.1097/FJC.0000000000001760","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001760","url":null,"abstract":"<p><p>Cardiometabolic complications represent a leading cause of morbidity and mortality among cancer survivors, who increasingly face a dual burden of residual oncologic risk and rising cardiovascular vulnerability. The shared pathophysiological mechanisms linking cancer, dyslipidemia, insulin resistance, and chronic inflammation foster an environment conducive to accelerated atherosclerosis, heart failure, and metabolic dysregulation. Hyperglycemia and hyperlipidemia, frequently coexisting in long-term cancer survivors, especially those exposed to cardiotoxic chemotherapies, hormonal therapies or corticosteroids, are key drivers of adverse cardiovascular outcomes. Despite this recognized risk, comprehensive preventive strategies in cardio-oncology remain limited and often rely on conventional therapies insufficient to fully address the complexity of cardiometabolic disease in this population. Notably, sodium-glucose co-transporter 2 inhibitors (SGLT2i) and proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i), have emerged as powerful tools in cardiovascular risk reduction. SGLT2i have demonstrated robust benefits in heart failure, renal protection and glycemic control, while PCSK9i provide profound and sustained reductions in low-density lipoprotein cholesterol (LDL-C), with emerging pleiotropic anti-inflammatory and anti-atherosclerotic effects. We propose that a combinatorial strategy integrating SGLT2i and PCSK9i may offer synergistic protection against the intertwined cardiometabolic risks seen in cancer survivors. This approach targets multiple mechanistic pathways, glucose and lipid metabolism, vascular inflammation, endothelial dysfunction, and organ remodeling, potentially redefining the standard of care in high-risk cardio-oncology populations. Further clinical investigation is warranted to validate this hypothesis and establish optimal therapeutic protocols.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anakinra in Fulminant Acute Myocarditis: A Case Report and Review of the Literature.","authors":"Sofia Morini, Simone Filomia, Gianluigi Saponara, Daniela Pedicino, Alessia d'Aiello, Gaetano Pinnacchio, Ludovico Luca Sicignano, Maria Lucia Narducci, Francesco Burzotta, Marco Giuseppe Del Buono, Tommaso Sanna","doi":"10.1097/FJC.0000000000001762","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001762","url":null,"abstract":"<p><p>Fulminant myocarditis (FM) is a critical condition with high mortality. Interleukin-1 (IL-1) is a key mediator of myocardial inflammation. We describe the case of a 19-year-old male with FM, hemodynamic deterioration refractory to standard treatment, and a marked systemic inflammatory response. The introduction of anakinra, an IL-1 receptor antagonist, led to rapid clinical, hemodynamic, and laboratory improvement. A literature review identifies other cases of severe/fulminant myocarditis with hyperinflammation that benefited from IL-1 blockade, despite heterogeneous etiologies. These data suggest that anakinra could be a valuable rescue therapeutic option in selected patients with FM and hyperinflammation. Randomized trials are needed to confirm the role of IL-1 blockade in this high-risk population, focusing on the pharmacology of the immune response.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remodeling Cardiovascular Research: Ready to Sacrifice Animal Models?","authors":"Fadi N Salloum, Frank J Raucci","doi":"10.1097/FJC.0000000000001759","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001759","url":null,"abstract":"","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145080569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current challenges for the diagnosis of HFpEF and possible simplification of the diagnostic approach.","authors":"Marco Bernardi, Michele Golino, Luigi Spadafora, Gianmarco Sarto, Maurizio Forte, Beatrice Simeone, Erica Rocco, Valentina Valenti, Sonia Schiavon, Antonio Esposito, Elena Di Florio, Lorenzo Scalia, Lorenzo Lo Sasso, Giacomo Frati, Giuseppe Biondi Zoccai, Francesco Versaci, Sebastiano Sciarretta","doi":"10.1097/FJC.0000000000001755","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001755","url":null,"abstract":"<p><p>Heart failure with preserved ejection fraction (HFpEF) is a prevalent and multifaceted clinical syndrome, often underdiagnosed due to its heterogeneous presentation and overlapping comorbidities. Recent randomized trials have demonstrated the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing heart failure hospitalizations and cardiovascular mortality. In this review, we analyze the main challenges of HFpEF diagnosis and discuss current diagnostic algorithms. Based on recent evidence and recommendations, we propose a possible way to simplify and accelerate the diagnostic process of HFpEF, to support an early initiation of disease-modifying therapies. An interactive web-based version of the proposed algorithm is available at www.hfpefdiagnosis.com for research or exploratory purposes.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145033399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CDK Inhibitor R547 Attenuates Pressure Overload-Induced Cardiac Hypertrophy via PI3K/AKT and TGF-β/Smad3 Signaling Pathways.","authors":"Chenglan Song, Qun Tang, Ling Liu, Genqing Zhou, Yong Wang","doi":"10.1097/FJC.0000000000001758","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001758","url":null,"abstract":"<p><p>Chronic stress-induced cardiac hypertrophy remains a critical precursor to heart failure, with current therapies limited by incomplete mechanistic targeting. Cyclin-dependent kinases (CDKs), pivotal regulators of cell cycle and stress signaling, are emerging therapeutic targets in cardiovascular pathologies. Using bioinformatics analysis of human hypertrophic cardiomyopathy datasets (GSE5500, GSE136308) and a murine transverse aortic constriction (TAC) model, we investigated the therapeutic effects of the CDK inhibitor R547 (10 mg/kg, intraperitoneal every 3 days) on pressure overload-induced cardiac remodeling. Cardiac function was assessed by echocardiography, while molecular mechanisms were probed through proteomics and pathway analyses. CDKs was significantly upregulated in heart tissues of human heart failure and TAC mice. R547 treatment attenuated cardiac hypertrophy (↓37.7% cardiomyocyte cross-sectional area; P<0.001) and fibrosis (↓70.8% collagen volume fraction; P<0.05) versus TAC controls. Echocardiographic improvements included preserved left ventricular ejection fraction (66±2.1% vs. 81±4.9% in TAC; P<0.05) and reduced ventricular wall thickening. Mechanistically, R547 concurrently inhibited PI3K/AKT/mTOR hypertrophic signaling and TGF-β/Smad3 fibrotic pathways, with corresponding downregulation of ANP, BNP, β-MHC, and collagen I. This study identifies CDK-driven signaling as a nodal regulator of pressure overload cardiomyopathy. The dual inhibition of PI3K/AKT and TGF-β/Smad3 pathways by R547 demonstrates superior efficacy in mitigating both structural and functional deterioration, positioning it as a promising multifactorial therapy for cardiac hypertrophy.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omaveloxolone promotes macrophage M2 polarization by activating the NRF2-Keap1 pathway and improves myocardial remodeling induced by pressure overload.","authors":"Qian Li, Wei Chen, Zhi-Shuo Hu, Yu-Ting Zhang, Fang-Zhong Weng, Lie Cheng, Cheng-Peng Li","doi":"10.1097/FJC.0000000000001757","DOIUrl":"https://doi.org/10.1097/FJC.0000000000001757","url":null,"abstract":"<p><p>Nuclear factor erythrocyte 2-associated factor 2 (Nrf2) is an important transcriptional regulator that plays a protective role in myocardial remodeling. Omaveloxolone (Omav) acts as an activator of Nrf2 and plays a protective role by decreasing oxidative stress and inflammation. The purpose of this study was to explore the role of Omav in myocardial remodeling and investigate the potential mechanism involved. Transverse aortic constriction was performed to construct a mouse cardiac remodeling model, and sham surgery was used as a control. The results showed that Omav treatment significantly improved TAC-induced myocardial remodeling and cardiac dysfunction. In addition, Omav treatment mitigated M1 macrophage polarization, promoted M2 macrophage polarization, and reduced the cardiac inflammatory response and oxidative stress. Cell experiments revealed that Omav can reduce the expression of p-STAT3 induced by PE, thereby inhibiting the polarization of M1 macrophages and promoting the polarization of M2 macrophages. However, the Nrf2 inhibitor ML385 significantly inhibited OMAV-mediated reduction of p-STAT3, macrophage polarization and activation of the NRf2-KEAP1 pathway. Omav activates the Nrf2-Keap1 pathway, affects STAT3 phosphorylation, ultimately alleviates M1 macrophage polarization, promotes M2 macrophage polarization, and improves myocardial remodeling. Omav may be a potential therapeutic agent for pathological myocardial remodeling.</p>","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145023367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}